Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCARTCS1A in Relapsed/Refractory Multiple Myeloma
NCT04142619Phase 1Terminated
- Sponsor
- Cellectis
- Start
- Nov 2019
- Primary completion
- Jun 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UCARTCS1A in multiple myeloma (MM), sponsored by Cellectis. Primary endpoints: Safety of UCARTCS1A at 24 months and Maximum Tolerated Dose. Started Nov 2019; status: terminated.
02
Drugs
UCARTCS1A
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04142619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04142619.